- KFSHRC to steer Medical Trials Concentrating on Aplastic Anemia and Graft vs. Host Illness
- Cellenkos to Assist Native Cell and Gene Remedy Manufacturing at KFSHRC
RIYADH, Saudi Arabia and HOUSTON, Could 22, 2025 /PRNewswire/ — King Faisal Specialist Hospital & Analysis Centre (KFSHRC) and Cellenkos® Inc., a Texas primarily based scientific stage biotech firm, have signed a strategic worldwide memorandum of understanding (MOU) following the Saudi-U.S. Funding Discussion board 2025, underscoring KFSHRC’s dedication to contributing to the development of medical innovation and strengthening strategic international collaborations and Cellenkos’ resolve to develop T regulatory (Treg) Cell Therapies for remedy of uncommon illnesses with unmet medical wants.
This landmark MOU establishes the muse for strategic collaboration between KFSHRC and Cellenkos to launch the primary scientific trial alliance between the Kingdom of Saudi Arabia and the US. The partnership will start with two scientific trials evaluating Cellenkos’ Treg merchandise for the remedy of Graft vs. Host Illness (GVHD) and Aplastic Anemia. This initiative will pave the best way for increasing into neurodegenerative illnesses, together with Amyotrophic Lateral Sclerosis (ALS) and cardiovascular issues. Concurrently, Cellenkos will help KFSHRC in constructing native infrastructure for cell and gene remedy manufacturing, coaching, and training.
“At KFSHRC, we stay deeply dedicated to enhancing remedy choices for sufferers with Aplastic Anemia and GVHD—situations that current critical challenges for a lot of people and households in our care. We look ahead to working along with Cellenkos in a approach that serves our sufferers and helps the development of tailor-made therapeutic options,” stated His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. “We’re thrilled about this partnership and alternative to work alongside a world-class establishment like KFSHRC,” stated Dr. Simrit Parmar, Founding father of Cellenkos and School at Texas A&M College. “Having seen firsthand the sophistication of KFSHRC’s bone marrow transplant program—together with regionally manufactured CD19 CAR T therapies, we’re assured that this collaboration will considerably scale back prices and enhance affected person entry. By using KFSHRC’s wire blood financial institution as an area supply for manufacturing, we will optimize scalability and impression. This marks the start of a transformative period in Treg cell remedy for international healthcare.”
About KFSHRC
KFSHRC is a number one healthcare, analysis, and training establishment acknowledged all through Saudi Arabia and the Center East. Established in 1975, the hospital is dedicated to offering world-class medical care and repeatedly advancing healthcare requirements throughout the Kingdom, the Center East, and the world. KFSHRC’s mission is to serve society with the best stage of healthcare and the most effective affected person expertise in an built-in training and analysis setting. KFSHRC performs greater than 300 Bone Marrow/Hematopoietic Stem Cell transplants a 12 months, with 250 allogeneic transplants, the place 11% of those transplants are for sufferers troubled with Aplastic Anemia; 5% troubled with Congenital BM Failure Syndromes, and one other 12% for different bone marrow failure syndromes. KFSHRC has in depth expertise in not solely treating sufferers with superior cell-based therapies similar to CAR T, with 58 remedies in 2024 alone, but additionally has performed greater than 10 CAR T and Gene Remedy scientific trials, has an on-site CAR-T manufacturing facility, and is constructing a big GMP Cell and Gene Remedy (CAGT) manufacturing facility on website. Moreover, KFSHRC Wire Blood Financial institution, launched in 2005, has roughly 3,000 saved wire blood items.
King Faisal Specialist Hospital & Analysis Centre has been ranked #1 within the Center East and North Africa, and #15 globally among the many world’s high 250 educational medical facilities. It is usually acknowledged as probably the most priceless healthcare model within the Center East in line with Model Finance 2024, and named one of many World’s Finest Good Hospitals by Newsweek journal for 2025.
Study extra at: www.kfshrc.edu.sa
About Cellenkos Inc.
Cellenkos is a clinical-stage biotechnology firm advancing allogeneic, off-the-shelf, wire blood-derived T regulatory (Treg) cell therapies for uncommon inflammatory and autoimmune illnesses. Cellenkos is a clinical-stage biotechnology firm primarily based in Houston, Texas, centered on growing off-the-shelf Treg cell therapies for uncommon inflammatory illnesses and autoimmune issues. Cellenkos’ Treg therapies, derived from allogeneic umbilical wire blood and its proprietary CRANE® platform allows tissue-directed Treg therapies with out HLA or ABO matching, appropriate for outpatient administration and fast point-of-care supply. The corporate is dedicated to advancing the event of those promising therapies to enhance the lives of sufferers with uncommon and underserved situations.
Study extra at: www.cellenkosinc.com
Media Contacts
KFSHRC: [email protected]
Cellenkos: [email protected]
Brand – https://mma.prnewswire.com/media/703732/Cellenkos_Logo.jpg
View authentic content material:https://www.prnewswire.co.uk/news-releases/cellenkos-inc-and-king-faisal-specialist-hospital–research-centre-sign-strategic-mou-to-advance-t-regulatory-cell-therapies-for-unmet-diseases-302463389.html
